MediWound Ltd. (MDWD) Stock Analysis — April 2026 Rating, Price, and Forecast
Company Overview — What Does MediWound Ltd. Do?
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel. MediWound Ltd. (MDWD) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Ofer Gonen and employs approximately 80 people. With a market capitalization of $208M, MDWD is one of the notable companies in the Healthcare sector.
MediWound Ltd. (MDWD) Stock Rating — Reduce (April 2026)
As of April 2026, MediWound Ltd. receives a Reduce rating with a composite score of 40.3/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.MDWD ranks #2,531 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, MediWound Ltd. ranks #325 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).
MDWD Stock Price and 52-Week Range
MediWound Ltd. (MDWD) currently trades at $17.85. The stock gained $0.08 (0.5%) in the most recent trading session. The 52-week high for MDWD is $22.50, which means the stock is currently trading -20.7% from its annual peak. The 52-week low is $14.14, putting the stock 26.2% above its annual trough. Recent trading volume was 81K shares, suggesting relatively thin trading activity.
Is MDWD Overvalued or Undervalued? — Valuation Analysis
MediWound Ltd. (MDWD) carries a value factor score of 25/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 7.00x, versus the sector average of 2.75x. The price-to-sales ratio is 2.70x, compared to 1.66x for the average Healthcare stock.
At current multiples, MediWound Ltd. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.
MediWound Ltd. Profitability — ROE, Margins, and Quality Score
MediWound Ltd. (MDWD) earns a quality factor score of 31/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -387.9%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -164.5% versus the sector average of -33.1%.
On a margin basis, MediWound Ltd. reports gross margins of 13.0%, compared to 71.5% for the sector. The operating margin is -95.9% (sector: -66.1%). Net profit margin stands at -149.5%, versus -58.7% for the average Healthcare stock. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.
MDWD Debt, Balance Sheet, and Financial Health
MediWound Ltd. has a debt-to-equity ratio of 21.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. Total debt on the balance sheet is $7M. Cash and equivalents stand at $9M.
MDWD has a beta of 0.84, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for MediWound Ltd. is 57/100, reflecting average volatility within the normal range for its sector.
MediWound Ltd. Revenue and Earnings History — Quarterly Trend
In TTM 2026, MediWound Ltd. reported revenue of $20M. Net income for the quarter was $-30M. Gross margin was 13.0%. Operating income came in at $-19M.
In FY 2024, MediWound Ltd. reported revenue of $20M. Net income for the quarter was $-30M. Gross margin was 13.0%. Revenue grew 8.2% year-over-year compared to FY 2023. Operating income came in at $-19M.
In FY 2023, MediWound Ltd. reported revenue of $19M. Net income for the quarter was $-7M. Gross margin was 19.1%. Revenue grew -29.5% year-over-year compared to FY 2022. Operating income came in at $-15M.
In FY 2022, MediWound Ltd. reported revenue of $26M. Net income for the quarter was $-20M. Gross margin was 49.7%. Revenue grew 11.5% year-over-year compared to FY 2021. Operating income came in at $-8M.
Over the past 8 quarters, MediWound Ltd. has demonstrated a growth trajectory, with revenue expanding from $3M to $20M. Investors analyzing MDWD stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.
MDWD Dividend Yield and Income Analysis
MediWound Ltd. (MDWD) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.
MDWD Momentum and Technical Analysis Profile
MediWound Ltd. (MDWD) has a momentum factor score of 44/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 45/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 63/100 reflects moderate short selling activity.
MDWD vs Competitors — Healthcare Sector Ranking and Peer Comparison
Within the Healthcare sector, MediWound Ltd. (MDWD) ranks #325 out of 838 stocks based on the Blank Capital composite score. This places MDWD in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.
Comparing MDWD against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full MDWD vs S&P 500 (SPY) comparison to assess how MediWound Ltd. stacks up against the broader market across all factor dimensions.
MDWD Next Earnings Date
No upcoming earnings date has been announced for MediWound Ltd. (MDWD) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.
Should You Buy MDWD? — Investment Thesis Summary
The quantitative profile for MediWound Ltd. suggests caution. The quality score of 31/100 flags below-average profitability. The value score of 25/100 indicates premium valuation.
In summary, MediWound Ltd. (MDWD) earns a Reduce rating with a composite score of 40.3/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on MDWD stock.
Related Resources for MDWD Investors
Explore more research and tools: MDWD vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare MDWD head-to-head with peers: MDWD vs AZN, MDWD vs SLGL, MDWD vs VMD.